|Amiodarone||long-term; also causes lung and thyroid toxicity|
|Glycogen storage disorders|
|Hemosiderosis||aka secondary hemochromatosis; often from long-term blood transfusions|
|Thorotrast administration (previous)||Thorotrast is carcinogenic contrast agent that was used between 1928 and the 1950s, primarily for cerebral angiography; deposits in reticuloendothelial system and is associated with HCC and cholangiocarcinoma|
In contrast (ha), diffuse decreased hepatic enhancement on CT is typically caused by diffuse fatty infiltration (hepatic steatosis), or diffuse metastatic involvement.
|Diffuse hepatic enhancement on a noncontrast CT|
Source: Fundamentals of Body CT